Institutional Review Board
The QAZIIM Institutional Review Board (IRB) is an independent ethical oversight body responsible for the ethical evaluation and continuous monitoring of biomedical and translational research conducted at the institute.
The IRB reviews studies involving:
-
human participants,
-
biological specimens,
-
genetic and multi-omics data,
-
clinical interventions, registries, and AI-based medical research.
The Board evaluates research protocols for:
-
scientific and ethical justification,
-
risk–benefit balance,
-
participant protection measures,
-
informed consent procedures,
-
data privacy and confidentiality,
-
compliance with applicable laws and international ethical frameworks.
The IRB operates in accordance with:
-
principles of the Declaration of Helsinki,
-
ICH-GCP (Good Clinical Practice) guidelines,
-
CIOMS international ethical guidelines,
-
and national regulatory requirements of the Republic of Kazakhstan.
IRB application documents
SOP-3. Initial Review of Clinical Research Documentation
SOP-4. Ethical Review of Clinical Research Studies
SOP-5. Ethical Review of Experimental (Preclinical) Research Studies
SOP-6. Review of Documentation for New Treatment and Diagnostic Technologies
SOP-7. Monitoring of Study Progress
SOP-8. Requirements for Informed Consent of Research Participants
SOP-9. Requirements for Investigators
SOP-10. Confidentiality and Data Protection
SOP-11. Safety Reporting
SOP-12. Serious Adverse Events (SAE) Reporting
SOP-13. Early Termination or Suspension of a Study/Trial
SOP-14. Review of the Final Study Report
